BiDil: A Case Study of Racial Medicine
Abstract
History
Current Issues
Conclusion
References & Links
Comments & questions to:
esson@macalester.edu
|
 |
        
|
BiDil: A Case Study of Racial Medicine
Conclusion
BiDi's
development, approval, and marketing have spurred fervent debate
amongst a significant number of actors in civil society. Many
stakeholders wield strong arguments for and against racial medicines.
While the citizen's role in this application of a controversial science
has been rather limited, opportunities for participation are present,
primarily through consumer-based opposition and social work striving to
achieve equal housing education, insurance, employment, etc. amongst
races. It is crucial society continues to fight the social inequalities
that truly lead to health disparities.
Further research would
be directed toward an empirical survey of BiiDil use: who are BiDil
patients in terms of class, location, affordability, etc.? Is it truly
exacerbating health disparities amongst the races? Also, a deeper
understanding of the FDA requirements for drug approval could
be helpful in understanding the legal loopholes that BiDil jumped
through if any exist (perhaps it was a legitimate approval). Finally,
the future of racial medicines is an inevitable topic for future study.
Will there be another racial drug? When? Which race will the next
racial medicine target?
|
 
Figures 7 - 10: Pill Collages
|
|
|
Last updated: 5.3.10
|
